Huron Digital Pathology

With a first-of-its-kind, AI-enabled image search engine called Lagotto, Huron Digital Pathology is revolutionizing how pathologists access the vast knowledge contained in the world’s pathology reports, hospital records, and clinical data, to drive efficiency and reduce diagnostic error. We just gained our first high profile customer for Lagotto in the US and are beginning to generate recurring software revenue. We are actively engaging with large hospitals and institutions keen to benefit from our solution. We are raising a Series A round to scale our sales efforts, expand our product portfolio and achieve regulatory approvals.

Presenter: Patrick Myles, Chief Executive Officer

KA Imaging Inc

KA Imaging has created color x-ray (Reveal™)which allows for soft tissue and bone separation resulting in better patient outcomes. Reveal™, has received USA FDA 510(k) clearance and Health Canada approval and the company is focusing on commercialisation. KA is raising $25M USD for commercialization infrastructure (sales, service and applications), marketing the hardware-as-a-service revenue model and AI development.

Presenter: Amol Karnick, President & CEO

Imaging-Related Technolog, Artificial Intelligence &, Medical DevicesDonald CudmoreJanuary 5, 2021

Nanovista Inc.

Nanovista is developing novel imaging agents for surgical oncology with the lead product, CF800, enabling cancer surgeons to visualize tumors in real time during surgery. Even the most skilled surgeons capture as little as 30-60% of the tumor margins in challenging disease areas. Nanovista's CF800 liposomal imaging agent accumulates specifically at tumor margins and is ideally suited to visualize all solid tumors. CF800 works with existing operating room near-infrared imaging equipment and illuminates tumors both at the surgery planning phase and inside the operating room, with the potential to significantly improve cancer surgery outcomes. The company is raising capital for Phase I development of CF800 in lung cancer and head and neck cancer.

Presenter: Anton Neschadim, Chief Executive

Oncology, Imaging-Related Technolog, Surgical TechnologiesDonald CudmoreJanuary 5, 2021

Oncoustics

Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Oncoustics applies AI to raw ultrasound signals from readily available handheld ultrasound devices to rapidly differentiate healthy versus diseased tissues. Oncoustics is a clinical-stage company with partnerships with several ultrasound OEMs, and FDA pre-sub and trials this year. Oncoustics is raising Series A capital to bring the first product to market (FDA clearance), and continue growing the data library for new indications, as well as grow the team.

Presenter: Ahmed El Kaffas, Founder